228 related articles for article (PubMed ID: 26692064)
1. A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab.
Abu Samra K; Valdes-Navarro M; Lee S; Swan R; Foster CS; Anesi SD
Eur J Ophthalmol; 2016 Apr; 26(3):e46-8. PubMed ID: 26692064
[TBL] [Abstract][Full Text] [Related]
2. A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma.
Hanna KS
Pharmacotherapy; 2016 Nov; 36(11):e183-e188. PubMed ID: 27716999
[TBL] [Abstract][Full Text] [Related]
3. Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: Case report.
Basilious A; Lloyd JC
Can J Ophthalmol; 2016 Feb; 51(1):e4-6. PubMed ID: 26874174
[No Abstract] [Full Text] [Related]
4. Case report: Bilateral uveitis and papillitis secondary to treatment with pembrolizumab.
Navarro-Perea C; Garcia-Gonzalez J; Perez-Blazquez E
Indian J Ophthalmol; 2019 Dec; 67(12):2075-2077. PubMed ID: 31755465
[TBL] [Abstract][Full Text] [Related]
5. BILATERAL SEROUS RETINAL DETACHMENT AND UVEITIS ASSOCIATED WITH PEMBROLIZUMAB TREATMENT IN METASTATIC MELANOMA.
de Vries EW; Schauwvlieghe AS; Haanen JB; de Hoog J
Retin Cases Brief Rep; 2022 Jul; 16(4):430-434. PubMed ID: 32243282
[TBL] [Abstract][Full Text] [Related]
6. Management of Chronic Hypotony Following Bilateral Uveitis in a Patient Treated with Pembrolizumab for Cutaneous Metastatic Melanoma.
Reid G; Lorigan P; Heimann H; Hovan M
Ocul Immunol Inflamm; 2019; 27(6):1012-1015. PubMed ID: 29672247
[No Abstract] [Full Text] [Related]
7. Safety of pembrolizumab for the treatment of melanoma.
Martin-Liberal J; Kordbacheh T; Larkin J
Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A;
N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173
[TBL] [Abstract][Full Text] [Related]
9. Chronic anterior uveitis in common variable immunodeficiency.
Oltra EZ; Morris C; Birnbaum AD; Tessler HH; Goldstein DA
Ocul Immunol Inflamm; 2011 Dec; 19(6):448-9. PubMed ID: 22106916
[TBL] [Abstract][Full Text] [Related]
10. Bilateral Drug-Induced Uveitis and Epiretinal Membrane during the Treatment of a Metastatic Cutaneous Melanoma.
Mozo Cuadrado M; Tabuenca Del Barrio L; Compains Silva E
Ocul Immunol Inflamm; 2021 Apr; 29(3):543-545. PubMed ID: 31755788
[No Abstract] [Full Text] [Related]
11. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
Robert C; Ribas A; Wolchok JD; Hodi FS; Hamid O; Kefford R; Weber JS; Joshua AM; Hwu WJ; Gangadhar TC; Patnaik A; Dronca R; Zarour H; Joseph RW; Boasberg P; Chmielowski B; Mateus C; Postow MA; Gergich K; Elassaiss-Schaap J; Li XN; Iannone R; Ebbinghaus SW; Kang SP; Daud A
Lancet; 2014 Sep; 384(9948):1109-17. PubMed ID: 25034862
[TBL] [Abstract][Full Text] [Related]
12. Bilateral uveitis and macular edema induced by Nivolumab: a case report.
Theillac C; Straub M; Breton AL; Thomas L; Dalle S
BMC Ophthalmol; 2017 Dec; 17(1):227. PubMed ID: 29195497
[TBL] [Abstract][Full Text] [Related]
13. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
[TBL] [Abstract][Full Text] [Related]
14. Vision loss with pembrolizumab treatment: A report of two cases.
Telfah M; Whittaker TJ; C Doolittle G
J Oncol Pharm Pract; 2019 Sep; 25(6):1540-1546. PubMed ID: 30997872
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory Papillitis in Uveitis: Response to Treatment and Use of Optic Nerve Optical Coherence Tomography for Monitoring.
Cho H; Pillai P; Nicholson L; Sobrin L
Ocul Immunol Inflamm; 2016; 24(2):194-206. PubMed ID: 25549180
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
Diem S; Keller F; Rüesch R; Maillard SA; Speiser DE; Dummer R; Siano M; Urner-Bloch U; Goldinger SM; Flatz L
J Immunother; 2016; 39(9):379-382. PubMed ID: 27662340
[TBL] [Abstract][Full Text] [Related]
17. New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient.
Miserocchi E; Cimminiello C; Mazzola M; Russo V; Modorati GM
Can J Ophthalmol; 2015 Feb; 50(1):e2-4. PubMed ID: 25677296
[No Abstract] [Full Text] [Related]
18. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
Longoria TC; Tewari KS
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma.
Aleksova J; Lau PK; Soldatos G; McArthur G
BMJ Case Rep; 2016 Nov; 2016():. PubMed ID: 27881588
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab-related Bilateral Ocular Hypotony, Uveitis, Cataracts, Exudative Retinal, and Choroidal Detachments: An Unusual Success Story.
Golash V; Almeida G
J Immunother; 2020; 43(9):283-285. PubMed ID: 32740318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
